Pharmacy & Therapeutics- August 2008 - (Page 486) CONTINUING EDUCATION CREDIT 79. Wenzel RG, Schwarz K, Padiyara RS. Topiramate for migraine prevention. Pharmacotherapy 2006;26(3):375–387. 80. Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005;28(6): 277–279. 81. Shaygannejad V, Janghorbani M, Ghorbani A, et al. Comparison of the effect of topiramate and sodium valproate in migraine prevention: A randomized blinded crossover study. Headache 2006; 46(4):642–648. 82. Krymchantowski A, Tavares C. Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting. Medscape Gen Med 2004;6(3):48. 83. Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache 2006;46(5):804–807. 84. Ashkenazi A, Benlifer A, Korenblit J. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia 2006;26(10):1199– 1202. 85. Gupta P, Singh S, Goyal V, et al. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache 2007;47(3):402–412. 86. Di Trapani G, Mei D, Marra C, et al. Gabapentin in the prophylaxis of migraine: A double-blind randomized placebo-controlled study. Clin Ther 2000;151(3):145–148. 87. Mathew N, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;141:119–128. 88. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997;17:101–102. 89. Rapoport AM, Sheftell FD, Tepper SJ, et al. Levetiracetam in the preventive treatment of transformed migraine. Curr Ther Res 2005;66:212–221. 90. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. JAMA 1983;250:2500–2502. 91. Markley GH, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 1984;34:973–976. 92. Solomon GD. Verapamil in migraine prophylaxis: A five-year review. Headache 1989;29(7):425–427. 93. Stewart DJ, Gelston A, Hakim A. Effect of prophylactic administration of nimodipine in patients with migraine. Headache 1988; 28:260–262. 94. Kahan A, Weber S, Amor B, et al. Nifedipine in the treatment of migraine in patients with Raynaud’s phenomenon. N Engl J Med 1983;308:1102–1103. 95. Lindegaard KF, Ovrelid L, Sjaastad O. Naproxen in the prevention of migraine attacks: A double-blind, placebo-controlled crossover study. Headache 1980;20:96–98. 96. Sargent J, Solbach P, Damasio H, et al. A comparsion of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 1985;25:320–324. 97. Welch KM, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985;35:1304–1310. 98. Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Arch Neurol 1985;42:582–584. 99. O’Neill BP, Mann JD. Aspirin prophylaxis in migraine. Lancet 1978;2:1179–1181. 100. Stensrud P, Sjaastad O. Clinical trial of a new anti-bradykinin antiinflammatory drug, ketoprofen (19,583 r.p.) in migraine prophylaxis. Headache 1974;14:96–100. 101. Mikkelsen BM, Falk JV. Prophylactic treatment of migraine with tolfenamic acid. Acta Neurol Scand 1982;66:105–111. 102. Diamond D, Solomon GD, Freitag FG, et al. Fenoprofen in the prophylaxis of migraine: A double-blind placebo controlled study. Headache 1987;27:246–249. 103. Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: A placebo-controlled double-blind crossover. Headache 1992;32(10):509–513. 104. Saper JRT, Winner PK, Lake AE. An open-label dose titration study of the efficacy of tizanadine HCl tablets in chronic daily headache prophylaxis. Headache 2001;41:357–368. 105. Hering-Hanit R. Baclofen for prevention of migraine. Cephalalgia 1999:19(6):589–591. 106. Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA 2003;289;65–69. 107. Schrader H, Stovner L, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomized, placebo controlled, crossover study. BMJ 2001;322:19–22. 108. Paterna S, Di Pasquale P, D’Angelo A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 2000;43:133–136. 109. Etminan M, Levine MA, Tomlinson G, et al. Efficacy of angiotensin II receptor antagonists in preventing headache: A systematic overview and meta-analysis. Am J Med 2002;112:642–646. 110. Sheftell F, Rapoport A, Weeks R, et al. Montelukast in the prophylaxis of migraine: A potential role for leukotriene modifiers. Headache 2000;40(2):158–163. 111. Brandes JL, Visser WH, Farmer MV, et al. Montelukast for migraine prophylaxis: A randomized double-blind, placebocontrolled study. Headache 2004;44:581–586. 112. LaPorta LD. Relief from migraine headache with aripiprazole treatment. Headache 2007;47(6):922–926. 113. Silberstein SD, Young WB, Hopkins MM, et al. Olanzapine in the treatment of refractory migraine and chronic daily headache (Abstract). Cephalalgia 2000;20:382. 114. Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (Botox) for treatment of migraine. Semin Cutaneous Med Surg 2001;20(2):93–100. 115. Silberstein S, Mathew N, Saper J, et al. Botox Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40:445–450. 116. Anand KS, Prasad A, Singh MM, et al. Botulinum toxin type A in prophylactic treatment of migraine. Am J Ther 2006;13(3):183– 187. 117. Vo AH, Satori R, Jabbari B, et al. Botulinum toxin type-A in the prevention of migraine: A double-blind controlled trial. Aviat Space Environ Med 2007;78(5 Suppl):B113–B118. 118. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type A prophylactic treatment of episodic migraine: A randomized, double-blind, placebo-controlled exploratory study. Headache 2007; 47(4):486–499. 119. Elkind AH, O’Carroll P, Blumenfeld A, et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006;7(10):688–696. 120. Freitag FG. Botulinum toxin type A in chronic migraine. Exp Rev Neurother 2007;7(5):463–470. 121. Medeiros FL, Medeiros PL, Valenca MM, et al. Simvastatin for migraine prevention. Headache 2007;47(6):855–856. 122. Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: A double-blind, multicentre, randomized placebo-controlled dose–response study. Cephalalgia 2002;22:523–532. 123. Lipton RB, Gobel H, Einhaupl K, et al. Petasites hybridus root (butterbur) is an effective treatment for migraine. Neurology 2004; 63:2240–2244. 124. Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: Reanalysis of efficacy criteria. Eur Neurol 2004;51: 89–97. 125. Sandor P, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 2005;64:713–715. 126. Peres MF, Zukerman E, da Cunha TF, et al. Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004;63;757. 127. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: A randomized trial. Headache 2004;44(9):885–890. 128. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology 1998;50:466–470. 129. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: Results from a prospective, multicenter, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16:257–263. 130. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the pro- 486 P&T® • August 2008 • Vol. 33 No. 8
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.